Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways.
Biohaven has licensed intellectual property from Yale University,Massachusetts General Hospital, Rutgers, Catalent, ALS Biopharma LLC and large pharmaceutical companies. The Company’s first drug candidate, BHV-0223, is a novel formulation of a glutamate-modulating agent, being developed under FDA 505(b)(2) guidelines for Amyotrophic Lateral Sclerosis (or Lou Gehrig’s disease). The FDA cleared the Company’s IND for BHV-0223 in August 2015, and Biohaven has completed a pharmacokinetic study in humans and is planning to launch a pivotal bioequivalence study by 4Q2016/1Q2017.
Biohaven’s second clinical compound, trigriluzole, is a New Molecular Entity (NCE) for neurodegenerative diseases, neuropsychiatric disorders and potentially cancer indications. The Company plans to advance other approaches and is actively exploring licenses for additional compounds.